#MadeInChina #COVID19Vaccine #FakeVaccine
Made-in-China Fake COVID19 Vaccine Sold Via Chinese WeChat
Source: Liberty Times, Taiwan #Aug13 https://news.ltn.com.tw/news/world/breakingnews/3259576
#CoronaVac #WeChat
Read more
https://t.me/guardiansofhongkong/24350
Made-in-China Fake COVID19 Vaccine Sold Via Chinese WeChat
Source: Liberty Times, Taiwan #Aug13 https://news.ltn.com.tw/news/world/breakingnews/3259576
#CoronaVac #WeChat
Read more
https://t.me/guardiansofhongkong/24350
#MadeInChina #COVID19Vaccine #FakeVaccine
Made-in-China Fake COVID19 Vaccine Sold Via Chinese WeChat
Currently, no COVID-19 vaccine has been proven and manufactured for use in the world. Howevet, a fake vaccine can already be found on the internet in China. This fake vaccine claims to be produced from a "well-known" pharmaceutical company. Each dose of vaccine is marked at 498 RMB (~ 72 USD).
According to Chinese media reports, netizens have put “fake vaccines” on WeChat for sale. A WeChat message reads, “Please contact me if you need a COVID-19 vaccine. We do export as well. But, you will be on a waitlist first due to limited supply.” Also, it claims that the first batch of vaccines will be officially on sale on 2 September 2020.
Another message reads, “A China-made vaccine is already available. One dose is 498 RMB. Each treatment needs three doses in total. Healthcare workers and those who need to go abroad have priority. The vaccine will be widely available by the end of this year.”
The name of the vaccine “CoronaVac an inactivated vaccine for SARS-CoV-2 (Vero cell)“ is printed on the package and the product’s barcode could be traced to Sinovac Biotech and Wuhan Institute of Biological Products Co., Ltd.
Source: Liberty Times, Taiwan #Aug13
https://news.ltn.com.tw/news/world/breakingnews/3259576
#CoronaVac #WeChat
Made-in-China Fake COVID19 Vaccine Sold Via Chinese WeChat
Currently, no COVID-19 vaccine has been proven and manufactured for use in the world. Howevet, a fake vaccine can already be found on the internet in China. This fake vaccine claims to be produced from a "well-known" pharmaceutical company. Each dose of vaccine is marked at 498 RMB (~ 72 USD).
According to Chinese media reports, netizens have put “fake vaccines” on WeChat for sale. A WeChat message reads, “Please contact me if you need a COVID-19 vaccine. We do export as well. But, you will be on a waitlist first due to limited supply.” Also, it claims that the first batch of vaccines will be officially on sale on 2 September 2020.
Another message reads, “A China-made vaccine is already available. One dose is 498 RMB. Each treatment needs three doses in total. Healthcare workers and those who need to go abroad have priority. The vaccine will be widely available by the end of this year.”
The name of the vaccine “CoronaVac an inactivated vaccine for SARS-CoV-2 (Vero cell)“ is printed on the package and the product’s barcode could be traced to Sinovac Biotech and Wuhan Institute of Biological Products Co., Ltd.
Source: Liberty Times, Taiwan #Aug13
https://news.ltn.com.tw/news/world/breakingnews/3259576
#CoronaVac #WeChat
自由時報電子報
武漢肺炎》中國「假疫苗」先開賣！ 外觀逼真一劑賣2100元 - 國際 - 自由時報電子報
武漢肺炎（新型冠狀病毒病，COVID-19）疫情蔓延全球，各國紛紛投入疫苗研發工作。沒想到，中國自家疫苗還沒上市，網路就先出現偽造知名藥廠生產、外觀逼真的「假疫苗」，一劑要賣人民幣498元（約新台幣2100元）。綜合中媒報導，中國微信有網民販售假疫苗，文案上寫「需要新冠疫苗的聯繫我，可做出口，產量低需排隊」，還聲稱批疫苗將會在9月2日正式上線。另有網民喊出，「498一支，總共打3支，已經出來了。醫護人員和出國人員可以先用。差不多年底，能普及了。」
Brazilian Federal Government Unwilling to Buy Chinese Vaccines, Only Buying Products Developed by British Pharmaceutical Companies and Oxford University
In an interview with local Brazilian media on 14th October, Sao Paulo State Health Secretary Jean Gorinchteyn confirmed that the Brazilian federal government had not appropriated funds to purchase the Wuhan Virus vaccine (CoronaVac) from China. Clinical trials of CoronaVac are being conducted in Brazil and the Butantan Institute of Sao Paulo State is in collaboration with research and development.
Gorinchteyn had also stated that in an earlier Ministry of Health meeting, the Brazilian federal government had confirmed they would only purchase vaccines jointly developed by British pharmaceutical company AstraZeneca and Oxford University and were not planning on purchasing CoronaVac. Besides the guaranteed purchase of 61 million doses of the Oxford vaccines that the Brazilian federal government had already committed to, authorities are unwilling to purchase additional vaccines, but did not explain the reason why funds were not appropriated to buy the Chinese vaccine.
#WuhanVirus #Brazil #vaccines #AstraZeneca #CoronaVac #Oxford #UK
Source: Stand News #Oct16
In an interview with local Brazilian media on 14th October, Sao Paulo State Health Secretary Jean Gorinchteyn confirmed that the Brazilian federal government had not appropriated funds to purchase the Wuhan Virus vaccine (CoronaVac) from China. Clinical trials of CoronaVac are being conducted in Brazil and the Butantan Institute of Sao Paulo State is in collaboration with research and development.
Gorinchteyn had also stated that in an earlier Ministry of Health meeting, the Brazilian federal government had confirmed they would only purchase vaccines jointly developed by British pharmaceutical company AstraZeneca and Oxford University and were not planning on purchasing CoronaVac. Besides the guaranteed purchase of 61 million doses of the Oxford vaccines that the Brazilian federal government had already committed to, authorities are unwilling to purchase additional vaccines, but did not explain the reason why funds were not appropriated to buy the Chinese vaccine.
#WuhanVirus #Brazil #vaccines #AstraZeneca #CoronaVac #Oxford #UK
Source: Stand News #Oct16
立場新聞 Stand News
【武漢肺炎】巴西聯邦政府不願買中國疫苗 只會採購英藥廠與牛津研發產品 | 立場報道 | 立場新聞
周三 (14/10) ，巴西聖保羅州衞生部部長 Jean Gorinchteyn 接受當地傳媒訪問時確認，聯邦...
Brazil President Refused to Buy Chinese Vaccine
Brazil, where the COVID-19 epidemic is severe, plans to launch a national vaccination program. The authorities once stated that they would use a Chinese vaccine, but this action aroused public opposition. Brazilian President Jair Bolsonaro said that he would not buy the Chinese vaccine.
BBC reported that a Bolsonaro supporter urged the authorities not to buy coronavirus vaccine from Sinovac, a Chinese company, on social media, to which Bolsonaro responded, "We will not buy the Chinese vaccine." He added that the Brazilian authorities have not yet approved the use of Sinovac vaccine.
São Paulo Governor João Doria once said the federal government would include CoronaVac, the vaccine from Sinovac, in National Vaccination Program, and agreed to purchase 46 million doses for the citizen of São Paulo. The vaccination program was planned to begin in January 2021. The Health Minister Eduardo Pazuello said on Tuesday (20 October) that the authorities would buy CoronaVac, but Bolsonaro directly rejected it.
#Brazil #NationalImmunizationProgram #Bolsonaro #JoãoDoria #EduardoPazuello #Sinovac #CoronaVac #BBC #COVID19 #ChineseVaccine
Source: The Stand News #Oct22
https://bit.ly/323uY0T
Brazil, where the COVID-19 epidemic is severe, plans to launch a national vaccination program. The authorities once stated that they would use a Chinese vaccine, but this action aroused public opposition. Brazilian President Jair Bolsonaro said that he would not buy the Chinese vaccine.
BBC reported that a Bolsonaro supporter urged the authorities not to buy coronavirus vaccine from Sinovac, a Chinese company, on social media, to which Bolsonaro responded, "We will not buy the Chinese vaccine." He added that the Brazilian authorities have not yet approved the use of Sinovac vaccine.
São Paulo Governor João Doria once said the federal government would include CoronaVac, the vaccine from Sinovac, in National Vaccination Program, and agreed to purchase 46 million doses for the citizen of São Paulo. The vaccination program was planned to begin in January 2021. The Health Minister Eduardo Pazuello said on Tuesday (20 October) that the authorities would buy CoronaVac, but Bolsonaro directly rejected it.
#Brazil #NationalImmunizationProgram #Bolsonaro #JoãoDoria #EduardoPazuello #Sinovac #CoronaVac #BBC #COVID19 #ChineseVaccine
Source: The Stand News #Oct22
https://bit.ly/323uY0T
Brazil Halts the Final Stage China Vaccine Trial, Claims Serious Adverse Reaction
The Brazilian National Health Surveillance Agency on Monday announced that it has suspended the clinical trials of China's Sinovac COVID-19 vaccines, citing "serious adverse reactions" that occurred during the testing last month (29 October), But the authority did not provide further details, nor explained why it took more than a week to announce the problem.
Sinovac Biotech has been cooperating with Butantan, an institute at the State of Sao Paulo, to develop COVID-19 vaccines, called CoronaVac. The institute was surprised by ANVISA's decision, said it said was investigating the incident and will held a press conference on Tuesday morning local time.
#China #Brazil #SaoPaulo #SinovacBiotech #Butantan #CoronaVac #ANVISA #COVID19 #WuhanVirus #Vaccine
Source: Stand News #Nov10
https://bit.ly/2H6uwYI
The Brazilian National Health Surveillance Agency on Monday announced that it has suspended the clinical trials of China's Sinovac COVID-19 vaccines, citing "serious adverse reactions" that occurred during the testing last month (29 October), But the authority did not provide further details, nor explained why it took more than a week to announce the problem.
Sinovac Biotech has been cooperating with Butantan, an institute at the State of Sao Paulo, to develop COVID-19 vaccines, called CoronaVac. The institute was surprised by ANVISA's decision, said it said was investigating the incident and will held a press conference on Tuesday morning local time.
#China #Brazil #SaoPaulo #SinovacBiotech #Butantan #CoronaVac #ANVISA #COVID19 #WuhanVirus #Vaccine
Source: Stand News #Nov10
https://bit.ly/2H6uwYI
Indonesian Pharmaceutical Factory Changed Their Mind on the Uncertain Data after Saying 97% Validity for Chinese Vaccination
Brazil, Turkey and countries in East Asia Regions subsequently purchased Chinese COVID-19 vaccination which the foreign press claims it as “Chinese Vaccination Diplomatic”. Indonesia is the most frontline among these countries as they have received 1.2 million doses of CoronaVac, COVID-19 vaccinations from Sinovac Biotech in Beijing. However, Bio Forma Company, an Indonesia state-owned pharmaceutical company, pointed yesterday (Dec 8) that according to their interim data, the CoronaVac achieves 97% effectiveness, but then changed their wordings to uncertain protectiveness of the vaccine less than a day after.
An Indonesian state-owned pharmaceutical factory PT Bio Farma, co-operating with Beijing Sinovac Biotech, has announced on Tuesday (Dec 8) that the interim data of CoronaVoc phase 3 clinical test shows its 97% of effective protection without providing details.
Sinovac Biotech immediately issued a statement that they have not received data on the effectiveness of CoronaVac phase 3 clinical test. Later in the same day, PT Bio Farma added that the effective rate of Sinovac Biotech vaccinations has not yet been determined and claimed that the complete report will release in Jan 2021. Both parties did not explain the reason for misunderstanding.
Source: Stand News #Dec09
https://bit.ly/2K6ghES
#Indonesia #Beijing #SinovacBiotech #CoronaVac #Vaccination #Validity #Effectiveness #COVID19 #Phase3ClinicalTest
Brazil, Turkey and countries in East Asia Regions subsequently purchased Chinese COVID-19 vaccination which the foreign press claims it as “Chinese Vaccination Diplomatic”. Indonesia is the most frontline among these countries as they have received 1.2 million doses of CoronaVac, COVID-19 vaccinations from Sinovac Biotech in Beijing. However, Bio Forma Company, an Indonesia state-owned pharmaceutical company, pointed yesterday (Dec 8) that according to their interim data, the CoronaVac achieves 97% effectiveness, but then changed their wordings to uncertain protectiveness of the vaccine less than a day after.
An Indonesian state-owned pharmaceutical factory PT Bio Farma, co-operating with Beijing Sinovac Biotech, has announced on Tuesday (Dec 8) that the interim data of CoronaVoc phase 3 clinical test shows its 97% of effective protection without providing details.
Sinovac Biotech immediately issued a statement that they have not received data on the effectiveness of CoronaVac phase 3 clinical test. Later in the same day, PT Bio Farma added that the effective rate of Sinovac Biotech vaccinations has not yet been determined and claimed that the complete report will release in Jan 2021. Both parties did not explain the reason for misunderstanding.
Source: Stand News #Dec09
https://bit.ly/2K6ghES
#Indonesia #Beijing #SinovacBiotech #CoronaVac #Vaccination #Validity #Effectiveness #COVID19 #Phase3ClinicalTest
#WuhanPneumonia #MadeinChina
China-Made #CoronaVac Only Scores 50% in General Efficacy Test
The Butantan Institute in Brazil announced that the China-made CoronaVac vaccine has a 50 percent general efficacy rate in late-stage trials.
Reuters described the results as disappointing. The rate means that CoronaVac is only 50 percent effective when preventing patients from contracting mild cases of coronavirus.
Although the minimum target set by the World Health Organisation is 50 percent, the efficacy of the Chinese vaccine is way behind the vaccines produced by Moderna at 94 percent and Pfizer/BioNTech at 95 percent.
Source: Apple Daily; RTHK #Jan13
https://news.rthk.hk/rthk/en/component/k2/1570113-20210113.htm
https://hk.appledaily.com/international/20210113/NEWV4SZV4NDVDO67XEBGGWPBUA/
China-Made #CoronaVac Only Scores 50% in General Efficacy Test
The Butantan Institute in Brazil announced that the China-made CoronaVac vaccine has a 50 percent general efficacy rate in late-stage trials.
Reuters described the results as disappointing. The rate means that CoronaVac is only 50 percent effective when preventing patients from contracting mild cases of coronavirus.
Although the minimum target set by the World Health Organisation is 50 percent, the efficacy of the Chinese vaccine is way behind the vaccines produced by Moderna at 94 percent and Pfizer/BioNTech at 95 percent.
Source: Apple Daily; RTHK #Jan13
https://news.rthk.hk/rthk/en/component/k2/1570113-20210113.htm
https://hk.appledaily.com/international/20210113/NEWV4SZV4NDVDO67XEBGGWPBUA/
Brazil Stops Purchasing more Coronavac Vaccine and Does not Recommend for the 3rd Dose Booster
Brazil is a major customer of China's Coronavac. However, due to the rising efficacy concerns against the COVID Delta variant, along with other vaccines becoming more accessible, the Brazilian government pauses the Coronavac vaccines purchases and encourages people not to use it for a third booster shot. The CoronaVac vaccine factory originally planned to be built in Brazil is also unknown whether it will be built as scheduled.
The Wall Street Journal mentions that Brazil has almost fully purchased 100 million doses of China’s CoronaVac shot. However, the Brazilian government no longer recommends using CoronaVac as a booster dose, but Pfizer instead due to the low protective rates of CoronaVac.
According to the Brazilian government data, the Chinese shot accounted for 80% of the doses at the beginning of the year due to the National Immunization Programme but now declines to less than 35%. The data also shows two-thirds of Brazilians have had one vaccine shot, and just over a third have had two doses.
Source: Stand News #Sep13
https://bit.ly/39t1w7W
#COVID19 #SinovacBiotech #Coronavac #Pfizer #Brazil #WallStreetJournal #Vaccine #Booster
Brazil is a major customer of China's Coronavac. However, due to the rising efficacy concerns against the COVID Delta variant, along with other vaccines becoming more accessible, the Brazilian government pauses the Coronavac vaccines purchases and encourages people not to use it for a third booster shot. The CoronaVac vaccine factory originally planned to be built in Brazil is also unknown whether it will be built as scheduled.
The Wall Street Journal mentions that Brazil has almost fully purchased 100 million doses of China’s CoronaVac shot. However, the Brazilian government no longer recommends using CoronaVac as a booster dose, but Pfizer instead due to the low protective rates of CoronaVac.
According to the Brazilian government data, the Chinese shot accounted for 80% of the doses at the beginning of the year due to the National Immunization Programme but now declines to less than 35%. The data also shows two-thirds of Brazilians have had one vaccine shot, and just over a third have had two doses.
Source: Stand News #Sep13
https://bit.ly/39t1w7W
#COVID19 #SinovacBiotech #Coronavac #Pfizer #Brazil #WallStreetJournal #Vaccine #Booster